Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study

Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study

Background: Immune checkpoint inhibitor (ICI) has become the standard therapy for metastatic non-small cell lung cancer (NSCLC) patients. However, no robust evidence on the efficacy and safety of ICI in elderly NSCLC patients has been established. Materials and Methods: This retrospective study aime...

Full description

Bibliographic Details
Main Authors: Satoshi Endo, Takayuki Honda, Kazuaki Sato, Natsushi Kubota, Tatsuhiko Kamoshida, Akifumi Mochizuki, Mayumi Fujii, Junichi Ochi, Yasunari Miyazaki, Yoshikazu Tsukada
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Immune checkpoint inhibitor
NSCLC
The elderly
Chemoimmunotherapy
Immune-related adverse event
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294223000771

Internet

http://www.sciencedirect.com/science/article/pii/S2468294223000771

Similar Items